Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO)
Vice President of the Asian Society of Clinical Oncology
Executive Committee Member of the Leukemia Expert Committee of the Chinese Society of Clinical Oncology
Leader of the Oncology Expert Group at the Capacity Building and Continuing Education Center of the National Health Commission
Editor in Chief of Leukemia and Lymphoma Journal
In 1979, he went to study at the Faculty of Medicine of the University of Tokyo in Japan and has been dedicated to the diagnosis and treatment of benign and malignant diseases of the blood system, particularly renowned in the industry for the treatment of leukemia and lymphoma. In 1982, the first in vitro multipotent hematopoietic progenitor cell culture system was established in China, filling the domestic gap. Since 1983, more than 1200 cases of acute promyelocytic leukemia have been treated with sequential therapy of retinoic acid and arsenic trioxide, with a 10-year disease-free survival rate of 85%, reaching the international advanced level. Published over 200 papers and more than 40 monographs in domestic and foreign journals, and won 20 national, provincial, and municipal science and technology awards. Undertook 8 national 863 major scientific research projects and 25 provincial and municipal scientific research projects.